Holen Sie sich die Stockscreener-App
412.22
1.19%
4.85
Handel nachbörslich:
411.31
-0.91
-0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$407.37
Offen:
$406.08
24-Stunden-Volumen:
1.05M
Relative Volume:
0.60
Marktkapitalisierung:
$105.69B
Einnahmen:
$11.39B
Nettoeinkommen (Verlust:
$3.64B
KGV:
29.46
EPS:
13.9904
Netto-Cashflow:
$3.50B
1W Leistung:
+0.47%
1M Leistung:
+4.48%
6M Leistung:
-16.86%
1J Leistung:
-14.97%
1-Tages-Spanne:
$405.45
$415.55
1-Wochen-Bereich:
$402.58
$422.73
52-Wochen-Spanne:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Can Vertex Pharmaceuticals Incorporated stock resist sector downturns2025 Key Highlights & Technical Pattern Based Signals - newser.com
Will Vertex Pharmaceuticals Incorporated bounce back from current supportWeekly Risk Report & Stepwise Entry/Exit Trade Alerts - newser.com
11 Newly Overvalued Stocks this Week - Morningstar
Griffin Asset Management Inc. Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsProfit Target & Weekly Market Pulse Alerts - newser.com
Promising Biotech Stocks To Follow NowOctober 11th - MarketBeat
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potentialJuly 2025 Technicals & AI Powered Buy/Sell Recommendations - newser.com
Apollon Wealth Management LLC Purchases 4,630 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Meritage Portfolio Management Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Vanguard Personalized Indexing Management LLC - MarketBeat
US Bancorp DE Acquires 1,324 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Commerzbank Aktiengesellschaft FI Has $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Galvin Gaustad & Stein LLC - MarketBeat
Aberdeen Group plc Has $128.20 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Callan Family Office LLC - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Blair William & Co. IL - MarketBeat
Vertex Pharma announces new share buybacks worth up to $4B - MSN
Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News - GuruFocus
Pharma Compliance Trends Revealed at PCC West - BioXconomy
Recovering from injury, Boston Celtics star Jayson Tatum laces up for Vertex campaign - PRWeek
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Quantitative breakdown of Vertex Pharmaceuticals Incorporated recent moveWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Vertex Pharmaceuticals Incorporated stock daily chart insightsJuly 2025 Setups & Risk Managed Investment Signals - newser.com
Trifecta Capital Advisors LLC Buys 802 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Optas LLC Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vontobel Holding Ltd. Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Weiss Ratings Reiterates "Hold (C+)" Rating for Vertex Pharmaceuticals (NASDAQ:VRTX) - MarketBeat
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market - Nasdaq
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Indicators - Markets Mojo
Is Vertex Stock Poised for Growth After Positive CRISPR Therapy Trial Results in 2025? - Yahoo Finance
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors - Business Wire
Prime Capital Investment Advisors LLC Cuts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Best Biotech Stocks To Follow NowOctober 6th - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $530.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Motley Fool
Vertex’s quest for a breakthrough in Type 1 diabetes - Pharma Voice
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
RBC Raises Price Target on Vertex Pharmaceuticals to $423 From $405, Keeps Sector Perform Rating - MarketScreener
Dohj LLC Purchases Shares of 857 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Smartest Growth Stock to Buy With $500 Right Now - Yahoo Finance
The 5 Most Powerful Women in Biopharma - BioSpace
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Stake Lifted by KLP Kapitalforvaltning AS - MarketBeat
Shell Asset Management Co. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
SteelPeak Wealth LLC Makes New $10.06 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Simplicity Wealth LLC Purchases 1,736 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals a Smart Investment After Recent FDA Approval for Sickle Cell Therapy? - Sahm
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd - Business Wire
Former Vertex COO named chief executive at Dravet-focused biotech - The Business Journals
What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet? - Yahoo Finance
Vertex Pharmaceuticals: Strong Growth Potential with Promising Product Launches and Robust Pipeline - TipRanks
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
1.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):